



Functional Identification and Structural Analysis of a New Lipoate Protein Ligase in *Mycoplasma hyopneumoniae*

Kemeng Zhu^{1†}, Huan Chen^{2,3†}, Jin Jin^{1†}, Ning Wang¹, Guixing Ma², Jiandong Huang^{3,4}, Youjun Feng⁵, Jiuqing Xin^{1*}, Hongmin Zhang^{2*} and Henggui Liu^{1*}

OPEN ACCESS

Edited by:

Jyl S. Matson,
University of Toledo, United States

Reviewed by:

Katleen Vranckx,
Applied Maths NV, Belgium
Benjamin Bernard Armando Raymond,
UMR5089 Institut de Pharmacologie
et de Biologie Structurale
(IPBS), France

*Correspondence:

Jiuqing Xin
xinjiuqing2001@126.com
Hongmin Zhang
zhanghm@sustech.edu.cn
Henggui Liu
liuhenggui@caas.cn

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Molecular Bacterial Pathogenesis,
a section of the journal
Frontiers in Cellular and Infection
Microbiology

Received: 10 January 2020

Accepted: 24 March 2020

Published: 21 April 2020

Citation:

Zhu K, Chen H, Jin J, Wang N, Ma G,
Huang J, Feng Y, Xin J, Zhang H and
Liu H (2020) Functional Identification
and Structural Analysis of a New
Lipoate Protein Ligase in *Mycoplasma*
hyopneumoniae.
Front. Cell. Infect. Microbiol. 10:156.
doi: 10.3389/fcimb.2020.00156

¹ State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin, China, ² Department of Biology, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment and SUSTech-HKU Joint Laboratories for Matrix Biology and Diseases, Southern University of Science and Technology, Shenzhen, China, ³ School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, ⁴ Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, ⁵ Department of Pathogen Biology and Microbiology, Zhejiang University School of Medicine, Hangzhou, China

Mycoplasma hyopneumoniae (*M. hyopneumoniae*) is the causative agent of pandemic pneumonia among pigs, namely, swine enzootic pneumonia. Although *M. hyopneumoniae* was first identified in 1965, little is known regarding its metabolic pathways, which might play a pivotal role during disease pathogenesis. Lipoate is an essential cofactor for enzymes important for central metabolism. However, the lipoate metabolism pathway in *M. hyopneumoniae* is definitely unclear. Here, we identified a novel gene, *lpl*, encoding a lipoate protein ligase in the genome of *M. hyopneumoniae* (Mhp-Lpl). This gene contains 1,032 base pairs and encodes a protein of 343 amino acids, which is between 7.5 and 36.09% identical to lipoate protein ligases (Lpls) of other species. Similar to its homologs in other species, Mhp-Lpl catalyzes the ATP-dependent activation of lipoate to lipoyl-AMP and the transfer of the activated lipoyl onto the lipoyl domains of *M. hyopneumoniae* GcvH (Mhp H) *in vitro*. Enzymatic and mutagenesis analysis indicate that residue K56 within the SKT sequence of Mhp H protein is the lipoyl moiety acceptor site. The three-dimensional structure showed typical lipoate protein ligase folding, with a large N-terminal domain and a small C-terminal domain. The large N-terminal domain is responsible for the full enzymatic activity of Mhp-Lpl. The identification and characterization of Mhp-Lpl will be beneficial to our understanding of *M. hyopneumoniae* metabolism.

SUMMARY

Lipoic acid is an essential cofactor for the activation of some enzyme complexes involved in key metabolic processes. Lipoate protein ligases (Lpls) are responsible for the metabolism of lipoic acid. To date, little is known regarding the Lpls in *M. hyopneumoniae*. In this study, we identified a lipoate protein ligase of *M. hyopneumoniae*. We further

analyzed the function, overall structure and ligand-binding site of this protein. The lipoate acceptor site on *M. hyopneumoniae* GcvH was also identified. Together, these findings reveal that Lpl exists in *M. hyopneumoniae* and will provide a basis for further exploration of the pathway of lipoic acid metabolism in *M. hyopneumoniae*.

Keywords: *Mycoplasma hyopneumoniae*, lipoate protein ligase, lipoate metabolism, crystal structure, *M. hyopneumoniae* GcvH

INTRODUCTION

Mycoplasma hyopneumoniae (*M. hyopneumoniae*) is the causative agent of a worldwide and chronic pneumonia in pigs known as swine enzootic pneumonia (Mare and Switzer, 1965; Maes et al., 2008). *M. hyopneumoniae* infection is associated with economic losses due to reduced daily weight gain and feed efficiency, increased mortality, and production costs because of medication and vaccination. Additionally, pigs are predisposed to infection with viruses and other bacteria after infection by *M. hyopneumoniae*. Previous studies have shown that *M. hyopneumoniae* is very difficult to isolate from the infected lungs of pigs and its growth is slow. These phenomena indicate that the metabolism of *M. hyopneumoniae* has specific characteristics. However, little is known about the metabolism of *M. hyopneumoniae*.

Lipoic acid is a sulfur-containing cofactor that is universally required for aerobic metabolism (Smith et al., 2004). Lipoic acid is required for the activity of enzymes involved in oxidative and single carbon metabolism, such as dehydrogenase (PDH), 2-oxoglutarate dehydrogenase (2-OGDH), and branched-chain keto-acid dehydrogenase (BCKDH). Specific enzymes catalyze the covalent attachment of lipoic acid to the acyltransferase (E2) subunit or H protein of the glycine cleavage system (GcvH) via an amide linkage between the ϵ -amino group of a specific lysine residue of these proteins and the lipoic acid carboxyl group (Reed and Hackert, 1990; Fujiwara et al., 1992; Reche and Perham, 1999). The metabolism of lipoic acid has been clearly elucidated in *Escherichia coli* (*E. coli*). When lipoic acid is available in the environment, *E. coli* LplA catalyzes both the activation of lipoate to lipoyl-AMP and the subsequent transfer of the activated lipoyl moiety to an acceptor protein with lipoyl domains (LDs) (Reed et al., 1958; Morris et al., 1994, 1995). If exogenous lipoic acid is absent, *E. coli* LipB and LipA will initiate the lipoate synthesis pathway *in vivo* (Cronan et al., 2005). In this synthesis pathway, LipB functions as an octanoyl-acyl carrier protein (ACP) transferase that transfers the octanoyl moiety from the fatty acid biosynthetic intermediate octanoyl-ACP to the LD of a lipoate acceptor protein (Morris et al., 1995; Zhao et al., 2005). LipA then catalyzes the insertion of a sulfur into octanoylated domains to yield dihydrolipoyl-LD, which is further oxidized to lipoyl-LD (Douglas et al., 2006). In addition to *E. coli*, the enzymes involved in lipoate modification of proteins have been found in most other organisms, including *Streptomyces coelicolor* (Cao and Cronan, 2015), *Mycobacterium tuberculosis* (Ma et al., 2006), *Bacillus subtilis* (Christensen et al., 2011b), *Listeria monocytogenes* (Christensen et al., 2011a), *Thermoplasma*

acidophilum (Kim et al., 2005), *Chlamydia trachomatis* serovar L2 (Ramaswamy and Maurelli, 2010), *Plasmodium falciparum* (Gunther et al., 2007), *Saccharomyces cerevisiae* (Hermes and Cronan, 2013), plants (Ewald et al., 2014), bovines (Fujiwara et al., 1997), and humans (Cao et al., 2018b).

M. hyopneumoniae is a prokaryotic organism. Although *M. hyopneumoniae* was discovered as early as 1965 (Mare and Switzer, 1965), the enzymes responsible for the lipoate modification of proteins are unclear. In this study, we explore important enzymes that participate in the metabolism of lipoic acid in *M. hyopneumoniae*. Here, a putative lipoate protein ligase (Lpl) was found in the genome of *M. hyopneumoniae* by sequence analysis. This putative protein was expressed and purified. Functional analysis confirmed that the protein exerts a function similar to that of Lpl *in vitro*. We then solved the crystal structure of the protein. The structure indicated that this putative Lpl has a three-dimensional structure similar to that of the *E. coli* LplA, although their protein sequences share minimal identity. As Lpl is an important enzyme in lipoic acid metabolism, these results will facilitate our understanding of lipoic acid metabolism in *M. hyopneumoniae*.

MATERIALS AND METHODS

Plasmid Construction

All plasmids used and constructed in this study are shown in Table 1. In brief, the putative *Mhp-lpl* (MHP_RS01680) and *Mhp H* gene, in which the TGA stop codons in the ORF were replaced with TGG, were commercially synthesized after being optimized with *E. coli* codon. The synthesized *Mhp-lpl* was amplified with the primer pairs P1-F/P1-R and inserted into pET32a(+) between NdeI and XhoI sites to obtain the recombinant plasmid pX1. The synthesized *Mhp H* was amplified with the primer pairs P2-F/P2-R and inserted into pET32a(+) between NdeI and XhoI sites to obtain the recombinant plasmid pX2. The genes of *E. coli*

TABLE 1 | Plasmids used in this research.

pET32a	T7 promoter expression vector	Lab stock
pX1	pET32a encoding <i>Mhp-Lpl</i>	This study
pX2	pET32a encoding <i>MhpH</i>	This study
pX3	pET32a encoding <i>E. coli</i> LplA	This study
pX4	pET32a encoding <i>E. coli</i> GcvH	This study
pX5	pET32a encoding <i>Mhp-lpl</i> large domain	This study
pX6	pET32a encoding <i>Mhp-lpl</i> small domain	This study

LplA and GcvH were amplified from the DH5 α strain with the primer pairs P3-F/P3-R and P4-F/P4-R, respectively. Both genes were inserted into pET32a(+) between NdeI and XhoI sites to obtain the recombinant plasmids pX3 and pX4, respectively. To express the large (1-254 aa) and small domains (260-344 aa) of Mhp-Lpl, the two domains were amplified from the synthesized *Mhp-Lpl* with the designed primer pairs P1-F/P5-R and P6-F/P1-R and inserted into pET32a(+) between NdeI and XhoI sites to obtain the recombinant plasmids pX5 and pX6, respectively. All primer sequences used in this research are listed in **Table 2**.

Protein Expression and Purification

To express and purify the recombinant proteins with a hexahistidine-containing tag at the C terminus, the recombinant vectors were transformed into *E. coli* BL21 (DE3) cells and cultured in Luria broth at 37°C. When the cells reached 0.5 at OD₆₀₀, a final concentration of 1 mM isopropyl 1-thio- β -D-galactopyranoside (IPTG) was added. After incubating for an additional 6 h at 37°C, the cells were harvested and lysed by sonication in lysis buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl) containing 20 mM imidazole. The crude lysate was centrifuged at 12,000 g for 20 min. The supernatant was applied to an affinity chromatography column of Ni-NTA-agarose. The proteins were eluted with lysis buffer containing 500 mM imidazole. The protein used for crystallization was further purified by HiTrap SP column chromatography (GE Healthcare) and size-exclusion column HiLoad™ 16/600 Superdex™ 200 pg chromatography (GE Healthcare). This protein was concentrated to 180 mg/ml and stored at -80°C for later use.

Production of a Monoclonal Antibody in Mice

To produce specific monoclonal antibodies against Mhp-Lpl in mice, 6- to 7-week-old mice were immunized with the purified protein emulsified with complete or incomplete Freund's adjuvant. After three immunizations with an interval of 2 weeks, the mice were sacrificed to isolate spleen cells. The hybridomas were produced and screened according to

the protocol described previously (Chen et al., 2018). In brief, splenocytes and mouse SP2/0 myeloma cells were fused at a ratio of 5:1 using PEG 1450 at 37°C. The resulting hybridoma cells were plated onto ten 96-well plates and initially grown in RPMI 1640 medium supplemented with 10% fetal bovine serum for 24 h. Then, hybridoma cells were selected with hypoxanthine-aminopterin-thymidine (HAT)-conditioned medium for 2 weeks. The supernatant from each well was assayed by ELISA plated with Mhp-Lpl. The positive hybridoma cells were harvested and plated onto 96-well plates at a density of 0.5 cells/well. The supernatant from the plated hybridomas was assayed again as described above. The positive hybridoma was expanded, cultured and frozen in liquid nitrogen.

Assay of Enzymatic Function of Lpl *in vitro*

The activity of the Lpl or the separate domains of Lpl was analyzed as described previously (Afanador et al., 2014; Cao and Cronan, 2015). In brief, the purified Lpl or the separate domains of Lpl were incubated in reaction buffer (50 mM sodium phosphate, pH 7.0) containing 5 mM ATP, 5 mM DTT, 1 mM MgCl₂, 1 mM lipoic acid and 20 μ M apo-GcvH. After incubation at 37°C for 4 h, the lipoylation of apo-GcvH protein in the reaction was determined with rabbit anti-lipoic acid polyclonal antibodies (Abcam) using a western blot assay.

Western Blot Analysis

To determine the lipoylation of apo-GcvH protein or expression of Lpl in *M. hyopneumoniae*, a western blot assay was carried out as described previously (Cao and Cronan, 2015). In brief, proteins were loaded and separated on a 12% SDS-polyacrylamide gel and transferred by electrophoresis to nitrocellulose membranes (Millipore) for 25 min at 25 V. The membranes were blocked with 5% non-fat milk in PBST buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 2 mM KH₂PO₄, 0.01% Tween-20). The membranes were first stained with a rabbit anti-lipoic acid primary antibody (1:7500; Abcam) or mouse anti-Lpl monoclonal antibodies for 30 min. After washing three times with PBST, Odyssey Dylight 800-conjugated goat anti-rabbit or mouse IgG antibody (1:8000; Abcam) was added and incubated for 30 min. After washing three times, the membranes were analyzed by using Odyssey CLX Image Studio software.

Mutagenesis of Mhp H Protein

Sixteen lysine residues (K2, K3, K13, K36, K40, K41, K45, K51, K56, K62, K66, K78, K81, K90, K95, and K97) in the Mhp H protein were individually mutated to alanine residues. Each mutant gene was commercially synthesized and inserted into pET32a between the first NdeI and XhoI restriction sites. The mutant Mhp H proteins were named K2A, K3A, K13A, K36A, K40A, K41A, K45A, K51A, K56A, K62A, K66A, K78A, K81A, K90A, K95A, and K97A.

Crystallization, Diffraction Data Collection and Structure Determination

Crystals of Mhp-Lpl were obtained by the hanging drop vapor diffusion method. In brief, protein solutions at 60 mg/ml were

TABLE 2 | Primers used in this research.

Primer name	Primer sequence(5' → 3')
P1-F	TTT <u>CATATG</u> TACCTGATTGAACCGAAAC
P1-R	TTT <u>CTCGAG</u> CAGCAGCAGGTTACAAATT
P2-F	TTT <u>CATATG</u> AAGAAGATCGCAAAT
P2-R	TTT <u>CTCGAG</u> AAAATCTTCCAGCTCATCAAAT
P3-F	TTT <u>CATATG</u> TCCACATTACGCCTGCT
P3-R	TTT <u>CTCGAG</u> CCCTTACAGCCCCGCCA
P4-F	TTT <u>CATATG</u> AGCAACGTACCAGCAGAA
P4-R	TTT <u>CTCGAG</u> CTCGTCTTCTAACAATGCTTCGTA
P5-R	TTT <u>CTCGAG</u> GCTCAGGCCCCACACAAAAT
P6-F	TTT <u>CATATG</u> AATTATAGTTTAAATCGCAGT

The underlined nucleotide sequences are the endonuclease sites.

mixed in a 1:1 ratio with reservoir solutions (0.2M (NH₄)₂SO₄, 0.1M sodium acetate, pH 4.0, 20% PEG 2000 MME) and incubated at 16 °C. Crystals appeared in 1 day and grew to a suitable size for data collection in 1–3 days. Native crystals were harvested and soaked in cryoprotectant (0.2M (NH₄)₂SO₄, 0.1M sodium acetate, pH 4.0, 20% PEG 2000 MME and 16% glycerol) and then quickly immersed in liquid nitrogen. For the assistance of phasing, the dipicolinate lanthanide complex Nd(DPA)₃ (Pompidor et al., 2010) at a final concentration of 125 mM was added to the cryoprotectant, and the crystals were soaked for 30 min before freezing. X-ray diffraction data were collected at 100 K on the BL17U1 and BL19U1 beamlines at the Shanghai Synchrotron Radiation Facility (SSRF) (Wang et al., 2018) and processed using HKL2000. The structure was solved using the SAS protocol of Auto-Rickshaw: the EMBL-Hamburg automated crystal structure determination platform (Panjekar et al., 2005).

The input diffraction data were prepared and converted for use in Auto-Rickshaw using programs of the CCP4 suite (Collaborative Computational Project, 1994). FA values were calculated using the program SHELXC (Sheldrick, 2010). Based on an initial analysis of the data, the maximum resolution for substructure determination and initial phase calculation was set to 2.8 Å. All 15 heavy atoms requested were found using the program SHELXD (Schneider and Sheldrick, 2002). The correct hand for the substructure was determined using the programs ABS (Hao, 2004) and SHELXE (Sheldrick, 2002). Initial phases were calculated after density modification using the program SHELXE (Sheldrick, 2002). The two-fold non-crystallographic symmetry (NCS) operator was found using the program RESOLVE (Terwilliger, 2003). Density modification, phase extension and NCS-averaging were performed using the program DM (Cowtan and Zhang, 1999). A total of 30.90% of the model was built using the program ARP/wARP (Perrakis et al., 2001; Morris et al., 2003). The initial model was further built and refined with Phenix (Adams et al., 2010). The data collected from native crystals were used for final refinement using the model from Nd-derivative data. After alternative cycles of refinement with Refmac5 (Murshudov et al., 2011) and manual building in Coot (Emsley et al., 2010), clear positive electron density was identified at the putative active site of Mhp-Lpl, and lipoyl-AMP was modeled into the density. The final model was evaluated by MolProbity, showing that 96% of the residues were in the Ramachandran favored region and allowed region. Data collection and model refinement statistics are listed in Table 3. The coordinates and structure factors were deposited in the Protein Data Bank with the access code 6JOM.

RESULTS

Sequence Analysis of a Putative Lpl From *M. hyopneumoniae*

Lpl is an important enzyme for the metabolism of lipoic acid, which plays a role as a cofactor in eukaryotes, most bacteria and some archaea. To address the Lpl in *M. hyopneumoniae*, the genome of *M. hyopneumoniae* strain 232 (accession number:

TABLE 3 | Data collection and refinement statistics.

	Mhp-Lpl native	Mhp-Lpl SAD
Data collection		
Space group	P4 ₁ 2 ₁ 2	P4 ₁ 2 ₁ 2
Cell dimensions		
<i>a</i> , <i>b</i> , <i>c</i> (Å)	100.32, 100.32, 155.58	102.44, 102.44, 161.47
α, β, γ (°)	90.00, 90.00, 90.00	90.00, 90.00, 90.00
Resolution (Å)	50~2.45 (2.54~2.45)*	50~2.30 (2.38~2.30)
<i>R</i> _{merge}	0.060 (0.758)	0.104 (0.729)
<i>I</i> / σ <i>I</i>	40.4 (3.5)	29.1 (5.5)
Completeness (%)	99.6 (99.1)	97.8 (95.2)
Redundancy	14.9 (14.9)	18.2 (18.7)
Refinement		
Resolution (Å)	50~2.45	50~2.30
No. reflections	29572 (2730)	36085
<i>R</i> _{work} / <i>R</i> _{free}	0.2007/0.2683	0.1959/0.2631
No. atoms	5736	
Protein	5431	
LAQ	68	
Water	237	
Ramachandran favored (%)	95.87	
allowed (%)	3.98	
outliers (%)	0.15	
<i>B</i> -factors	67.10	
Protein	67.41	
LAQ	73.75	
Water	59.93	
R.m.s. deviations		
Bond lengths (Å)	0.010	
Bond angles (°)	1.75	

*Values in parentheses are for highest-resolution shell.

NC_006360) was searched. MHP_RS01680, which was annotated as a lipote protein ligase, was found. The nucleotide sequence of MHP_RS01680 contains 1032 bp encoding 343 amino acids (Figure 1A). The amino sequence shares 7.5% to 36.09% identity with LplA sequences of other species deposited in GenBank. The protein sequence alignment showed that the sequences with higher identity include LplA2 (36.09%) and LplA1 (35.58%) from *Enterococcus faecalis*, LplA from *Streptococcus pneumoniae* (33.54%), *E. coli* (26.49%), and *Bos Taurus* (24.17%), respectively (Figure 1B). There are 11 *M. hyopneumoniae* strains of which the genomes have been deposited into GeneBank. Protein alignment of Lpls among these strains indicated that they are highly conserved with sequence identity between 89 and 99.9% (Figure S1). As the gene was derived from automated computational analysis using a gene prediction method, it is not known whether this gene is expressed *in vivo*. To test the expression of the putative protein in *M. hyopneumoniae*, the MHP_RS01680 nucleotide sequence with all TGA codons within the open reading frame (ORF) substituted with TGG was synthesized and inserted into the pET32a vector. The protein encoded by MHP_RS01680 was induced and expressed in the




FIGURE 1 | Sequence analysis of a putative Lpl (MHP_RS01680) from *M. hyopneumoniae*. (A) The open reading frame of the putative Lpl cloned from the genome of *M. hyopneumoniae*. (B) Protein sequence alignment among the putative Lpl from *M. hyopneumoniae* and LplA molecules from *Enterococcus faecalis* (*E. faecium*), *Streptococcus pneumoniae* (*S. pneumoniae*), *Escherichia coli* (*E. coli*) and *Bostaurus* (bovine). Residues labeled with an asterisk implicate key differences at ligand binding sites between Mhp-Lpl and LplA molecules from other species.

E. coli BL21 strain and subsequently purified (Figures 2A,B). The purified protein was used to immunize mice to produce a monoclonal antibody using a hybridoma technique. As

shown in Figure 2C, the produced monoclonal antibodies could specifically recognize the purified proteins in the western blot assay. This result indicated that the monoclonal antibody was




FIGURE 2 | Confirming putative Lpl (MHP_RS01680) existence in *M. hyopneumoniae*. **(A)** The gene fragment of MHP_RS01680 from *M. hyopneumoniae* was inserted into the prokaryotic expression vector pET32a between NdeI and XhoI sites. The constructed recombinant plasmid was identified by double digestion with NdeI and XhoI enzymes. Lane 1, DL5000 DNA marker. Lane 2, digested recombinant plasmid. **(B)** MHP_RS01680-encoded protein was expressed in the *E. coli* BL21 (DE) strain, purified and analyzed by SDS-PAGE. Lane M, protein marker (kD); lane 1, the purified protein. **(C)** The MHP_RS01680-encoded protein was probed with the produced monoclonal antibody in the western blot assay. Lane M: protein marker (kD); lane 1, the purified MHP_RS01680-encoded protein. **(D)** The MHP_RS01680-encoded protein in *M. hyopneumoniae* was analyzed by western blotting using the specific monoclonal antibody. Lane M, protein marker (kD); lane 1, The MHP_RS01680-encoded protein in *M. hyopneumoniae*.

successfully produced. The monoclonal antibody was further used to detect MHP_RS01680 expression in *M. hyopneumoniae*. As shown in **Figure 2D**, when the total proteins of the *M. hyopneumoniae* J strain were extracted and subjected to western blotting, a protein band with a size of ~40 kD appeared, which is equal to the size deduced from the MHP_RS01680 nucleotide sequence. This result confirmed the expression of MHP_RS01680 in *M. hyopneumoniae*.

Functional Analysis of the Putative *M. hyopneumoniae* Lpl *in vitro*

Although MHP_RS01680 is annotated as a lipote protein ligase in *M. hyopneumoniae*, it is not known whether this protein is able to transfer lipoic acid to the acceptor protein, which is the functional phenotype of Lpl proteins. To characterize the function of MHP_RS01680, *E. coli* GcvH protein and LplA were expressed and purified (**Figures 3A,B**). The lipoic acid transfer assay was carried out *in vitro*. As shown in **Figures 3D,E**, although *E. coli* LplA could successfully transfer lipoic acid to *E. coli* GcvH, the MHP_RS01680-encoded protein failed. As *E. coli* GcvH is able to accept the lipote transferred by Lpl from other species (Cao and Cronan, 2015), this phenomenon probably resulted from two possibilities: the MHP_RS01680-encoded protein does not function as an Lpl or this protein cannot recognize *E. coli* GcvH as a lipote acceptor protein. To further investigate these questions, the *M. hyopneumoniae* *gcvh* genes in the genomes of different strains were analyzed. It was found that *M. hyopneumoniae* GcvH (Mhp H) proteins are highly conserved (**Figure S2**). According to this result, Mhp H from one strain was expressed and purified (**Figure 3C**). The lipote transfer assay was carried out. As shown in **Figure 3F**, lipoic acid was successfully transferred to the Mhp H protein by the MHP_RS01680-encoded protein. This result indicates that the MHP_RS01680-encoded protein is an Lpl in *M. hyopneumoniae*



(Mhp-Lpl). However, *E. coli* LplA fail to catalyze Mhp H modification by lipoic acid (**Figure 3G**).


Identification of the Lipote Acceptor Site on GcvH Recognized by Mhp-Lpl

In the glycine cleavage system, GcvH, as an acceptor protein for lipote, is generally conserved. *E. coli* GcvH accepts the lipote transferred by Lpl proteins from other species (Cao and Cronan, 2015). Here, Mhp-Lpl cannot transfer lipote to *E. coli* GcvH, indicating that the recognition site on the acceptor protein for Mhp-Lpl is different from that of the Lpls from other species. As the lipote is transferred to the lysine residue on the acceptor protein, we first screened the lysine residues accepting the transferred lipoyl moiety on the Mhp H protein. A total of 16 lysine residues on the Mhp H protein were individually mutated to alanine residues. All mutant Mhp H proteins were used to analyze the ability of accepting the lipoyl moiety. As shown in **Figure 4**, of all the mutant Mhp H proteins, only the mutant protein K56A was not able to accept the lipoyl moiety. This result indicated that K56 was the amino residue accepting the lipoyl moiety transferred by Mhp-Lpl. This residue is within the SKT amino acid sequence (**Figure 4A**).

Overall Structure of Mhp-Lpl

Mhp-Lpl was crystallized in the space group of P4₁2₁2, and there are two Mhp-Lpl molecules in the asymmetric unit (**Figure 5A**). Although the amino acid sequence identity between Mhp-Lpl and LplA-2 from *E. faecalis* (Ef-LplA-2) is 36.09%, the structure determination by molecular replacement method using Ef-LplA-2 as a searching model was unsuccessful, indicating possible structural variation between these two proteins. The lanthanide compound Nd(DPA)₃ was soaked into the Mhp-Lpl crystals, and the structure was solved by a single-wavelength anomalous dispersion method. Most of the amino acid residues could be





clearly traced, except residues between 173 and 183, part of the adenylate binding loop following the helix $\alpha 5$, which is also disordered in Ef-LplA-2 (PDB code 5IBY) and LplA from *E. coli* (Ec-LplA, PDB code 1X2H).


Mhp-Lpl is composed of a large N-terminal domain (residues 1–254), a small C-terminal domain (residues 260–344), and a short polypeptide (residues 255–259) between the two domains (Figure 5A). The N-terminal domain comprises two β -sheets, a large mixed β -sheet comprising seven strands ($\beta 1$, $\beta 2$, $\beta 6$ – $\beta 10$) and a small mixed β -sheet comprising three strands ($\beta 3$ – $\beta 5$), with seven α -helices ($\alpha 1$ – $\alpha 7$) surrounding the β -sheets. The C-terminal domain comprises three helices ($\alpha 8$ – $\alpha 10$) and a β -sheet composed of three strands ($\beta 11$ – $\beta 13$). The two molecules in the asymmetric unit are almost identical, with a root mean square deviation (rmsd) value of 0.42 for all superimposable $C\alpha$ atoms. The overall structure of Mhp-Lpl is similar to those of Ef-LplA-1 in complex with lipoate (PDB code 5IJ6) and Ef-LplA-2 in complex with lipoyl-AMP (PDB 5ICL), with rmsd values of 1.48 and 1.73 for approximately 300 superimposable $C\alpha$ atoms, respectively (Figure 5B). In contrast, Mhp-Lpl shows large variations with LplA molecules from *E. coli* (Ec-LplA, PDB code 1X2G, unliganded form) (Fujiwara et al., 2005) and *S. pneumoniae* (Sp-LplA, PDB code 1VQZ, unliganded form) with rmsd values of 2.88 and 2.61, respectively (Figure 5C). The relatively large rmsd values also indicate why the molecular replacement method failed to yield a reasonable solution. Although Mhp-Lpl binds to lipoyl-AMP at its active site (described in the following section), it adopts a closed conformation similar to those of Ef-LplA-2 (PDB code 5ICL) and the unliganded Ec-LplA (PDB code 1X2G). Upon ligand binding, Ec-LplA

(PDB code 3A7R) (Fujiwara et al., 2010) undergoes dramatic conformational changes and adopts a stretched conformation similar to that of bovine LplA (BT-LplA, PDB code 2E5A) (Figure 5C) (Fujiwara et al., 2007), whereas both unliganded and liganded bovine LplA adopt a stretched conformation and no dramatic conformational changes are present upon ligand binding (Fujiwara et al., 2010).

Ligand Binding Site of Mhp-Lpl

Mhp-Lpl was expressed in *E. coli* and purified by Ni-NTA affinity chromatography, cation exchange column sulfopropyl (SP) chromatography and size-exclusion column chromatography. The structural determination clearly showed an extra positive density at the putative active site (Figure 5A) between the two β -sheets in the N-terminal domain resembling AMP conjugated with a fatty acid. The AMP part could be fitted into the density unambiguously, while the fatty acid part indicated a linear structure in contrast to the ring structure in lipoic acid (Figure 6A). This fatty acid is longer than octoic acid (Figure 6A), and the separation and identification of the bound molecule by mass spectrometry was unsuccessful. As an anti-lipoic acid monoclonal antibody can also recognize this molecule (Figure 7A), we sought to determine whether this molecule could be transferred to the Mhp H protein as a substrate. As shown in Figure 7B, although the molecule existed at the active site in the purified Mhp-Lpl protein expressed in *E. coli*, the Mhp H protein could not be modified in the absence of lipoic acid. This result indicates that this bound molecule is not the functional substrate for Mhp-Lpl.

To clearly see the interaction between Mhp-Lpl and lipoic acid, Mhp-Lpl was first reacted with ATP and lipoic acid and then





crystallized after further purification. As shown in **Figure 6B**, lipoyl-AMP could be modeled into the density, despite its partial occupancy. Similar to lipoyl-AMP molecules in Ec-LplA (PDB code 3A7R) and Ef-LplA-2 (PDB code 5ICL), the lipoyl-AMP in Mhp-Lpl also adopts a U-shaped conformation at the bifurcated active site sandwiched between the lipoyate-binding loop (residues 72-83, RRDTGGGAIYLD) and the large β -sheet of the N-terminal domain. The AMP part of lipoyl-AMP forms extensive hydrophobic interactions with the surrounding residues, including I80, L82, K138, L158, I166, L170, and V189 (**Figure 6C**). Among these residues, K138 forms an additional hydrogen bond with the carbonyl oxygen of lipoyl-AMP and plays essential roles in both lipoyate adenylation and lipoyate transfer reactions as shown in *E. coli* LplA (Fujiwara et al., 2010). In addition to the nitrogen atoms in the adenine ring, the ribose and phosphate groups also form hydrogen bonds with neighboring residues or water molecules. The aliphatic moiety of lipoyic acid is enclosed in a hydrophobic tunnel formed by residues L20, Y40, T75, C90, A143, and Y152 (**Figure 6C**).

Structural superposition revealed several key differences at the ligand binding sites between Mhp-Lpl and LplA molecules from other species. The residues corresponding to residue Q47 in Mhp-Lpl all have a small side chain, such as isoleucine or valine, in the LplA proteins from other

species (**Figure 1B**). The large-sized side chain of residue Q47 in Mhp-Lpl pushes the dithiolane ring of the lipoyl moiety away and flips toward the large β -sheet in the N-terminal domain (**Figure 6D**). Correspondingly, the otherwise conserved histidine residue in LplA from other species at position 154 (**Figure 1B**) is replaced by a glycine residue in Mhp-Lpl, which enables the encapsulation of the dithiolane ring of the lipoyl moiety. Moreover, the conserved valine residue in the lipoyate-binding loop (77 in Ec-LplA and 75 in Ef-LplA-2, **Figure 1B**) is substituted with an isoleucine residue (I80, **Figures 6C,D**), which enhances the hydrophobic interaction with lipoyl-AMP and explains why it is difficult to remove the unidentified AMP-fatty acid conjugate from Mhp-Lpl expressed in *E. coli*.

The Large Domain Is Responsible for the Overall Lipoylation of Mhp H

The overall lipoylation reaction of GcvH contains two steps: activation of lipoyic acid with ATP to form lipoyl-AMP and the lipoyl moiety transfer to GcvH protein. Similar to other Lpls, Mhp-Lpl molecule contains two domains, the large and small domains. To examine the roles of the large and small domains of Mhp-Lpl in the overall lipoylation reaction of Mhp H protein, the large and small domains were first expressed and purified (**Figure 8A**). Their functions were analyzed *in*



vitro. As shown in **Figure 8B**, whether a small domain is present or absent, the large domain is able to catalyze Mhp H lipoylation. However, if the large domain was not added, then lipoate was not detected on Mhp H with the anti-lipoic acid polyclonal antibody. These results indicated that the large domain fulfills the complete catalytic function of the Mhp-Lpl enzyme, including activation of lipoic acid with ATP to form lipoyl-AMP and then catalyzing the transfer of the lipoyl moiety from lipoyl-AMP to Mhp H. However, the small domain was not required in the entire process of Mhp H lipoylation.

DISCUSSION

Lipoic acid is an important cofactor in most microbes. It is essential for the function of several key enzymatic complexes of central metabolism. The metabolism of lipoic acid is clearly explored in *E. coli* (Miller et al., 2000; Jordan and Cronan, 2003). Here, a new lipoate protein ligase from *M. hyopneumoniae* was verified, and its structure was solved. This analysis is the first functional identification of Lpl in *M. hyopneumoniae*. The

results will help disclose the metabolism of lipoic acid in *M. hyopneumoniae* and facilitate our understanding of the process of lipoic acid metabolism in *M. hyopneumoniae*. Protein sequence alignment indicates that the Lpls are highly conserved among the different strains of *M. hyopneumoniae* (**Figure S1**). However, it has not been investigated how conserved lplA is in other mycoplasma species. In contrast to the high conservation of Lpls in different strains of *M. hyopneumoniae*, Lpl from *M. hyopneumoniae* has marginal identity with Lpls from other species (**Figure 1B**). This result is similar to that for other Lpls, such as that from *S. coelicolor* (Cao and Cronan, 2015). GcvH is an acceptor protein for activated lipoic acid in most species. Previous reports showed that *E. coli* GcvH is able to accept the lipoyl moiety transferred by lipoate protein ligase of other species (Cao and Cronan, 2015). However, our research showed that Mhp-Lpl failed to lipoylate *E. coli* GcvH. Comparison of the lipoylated sites on the *E. coli* GcvH and Mhp H showed that the lysine residues modified by lipoate attachment to *E. coli* GcvH are typical VKA sequence, while those in Mhp H are within the SKT sequence (**Figure 4**). This difference is probably the reason for the failure of lipoylation of *E. coli* GcvH by Mhp-Lpl. Previous studies showed that the lipoylation of lysine was not affected when the residues flanking the modified lysine were replaced with aspartate, methionine, alanine or threonine residues (Berg et al., 1994; Reche and Perham, 1999; Cao and Cronan, 2015). However, our result is not consistent with this conclusion.

In this research, the structure of Mhp-Lpl has been solved. Mhp-Lpl comprises two domains, a large N-terminal domain and a small C-terminal domain (**Figure 5A**). The structural arrangement of this protein is similar to that of *E. coli* (Fujiwara et al., 2005; Kim et al., 2005; McManus et al., 2006). The fully functional lipoate protein ligase has been found in many species. These ligases could be divided into three types. The first type is LplA in both *E. coli* and *S. pneumoniae*, which contains a large N-terminal domain and a small C-terminal domain. The binding pocket of the substrate resides in the interface between the two domains (Fujiwara et al., 2005, 2010). The second type is the LplA found in *S. coelicolor*, which also contains a large domain and a small domain. However, their orientation is reversed compared with that of *E. coli* (Cao and Cronan, 2015). The third type of Lpl is found in the thermophile archaeon *T. acidophilum*, in which the fully functional ligase is composed of two separate proteins, LplA and LplB, encoded by adjacent genes (Posner et al., 2009, 2013). Both LplA and LplB are required for lipoyl-AMP formation, but LplA alone is sufficient for lipoyl transferase activity (Posner et al., 2013). The crystal structure shows that the two *T. acidophilum* proteins interact to form a structure with a domain orientation similar to that of the *E. coli* LplA (Posner et al., 2013). This research indicated that Mhp-Lpl is a fully functional lipoate protein ligase. However, different from the LplA from *S. coelicolor*, in which both the large and small domains are required to activate lipoate to lipoyl-AMP and the large domain is sufficient for lipoyl transfer activity (Cao and Cronan, 2015), the large domain of Mhp-Lpl is sufficient for both the activation and transfer of lipoic acid to receptor protein (**Figure 8B**).

Previous studies have indicated two different pathways of lipoic acid metabolism in *E. coli* (Morris et al., 1995; Cronan et al., 2005; Cronan, 2014). These two pathways are activated in the environment with or without lipoic acid and catalyzed by different enzymes. To date, there are no reports regarding lipoic acid metabolism in *M. hyopneumoniae* and other mycoplasma species. It is unclear whether *M. hyopneumoniae* has two pathways to metabolize lipoic acid, as in *E. coli*. Here, Mhp-Lpl was identified as one enzyme responsible for lipoic acid metabolism *in vitro*. However, the environment in which these proteins play a role *in vivo*, in presence or absence of lipoic acid, remains unknown. In addition, there are two different mechanisms of lipoate synthesis described in bacteria: the *E. coli* LipB-LipA pathway and a more complex pathway in *B. subtilis* that requires two additional proteins (Christensen et al., 2011b; Martin et al., 2011). Up to now, there is no molecular system available to knock out *lpl* gene on the *M. hyopneumoniae* genome and therefore the function of Mhp-Lpl could not be further validated *in vivo* in this research.

Previous research indicated that the enzymes responsible for the lipoate metabolism are very important for the growth of the organisms (Wang et al., 2017; Cao et al., 2018a). Therefore, Mhp-Lpl might be a potential drug target to explore as demonstrated by the development of Lpl inhibitors which inhibited the growth of *P. falciparum* dramatically (Allary et al., 2007). This strategy is also widely applied in other metabolic enzymes. For example, the molecules which inhibit the activity of the enzymes responsible for the metabolism of biotin have been explored to inhibit the growth of *Mycobacterium tuberculosis*, *Staphylococcus aureus*, *E. coli* and so on (Brown and Beckett, 2005; Duckworth et al., 2011; Feng et al., 2016). Our work identified a functional Lpl in *M. hyopneumoniae* and the structure of this enzyme may facilitate potential drug design against *M. hyopneumoniae* infection.

DATA AVAILABILITY STATEMENT

The datasets generated for this study can be found in the Protein Data Bank (PDB), the access code 6JOM.

REFERENCES

- Adams, P. D., Afonine, P. V., Bunkóczi, G., Bunkóczi, V. B., Davis, I. W., Echols, N., et al. (2010). PHENIX: a comprehensive python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 66, 213–221. doi: 10.1107/S0907444909052925
- Afanador, G. A., Matthews, K. A., Bartee, D., Gisselberg, J. E., Walters, M. S., Freel Meyers, C. L., et al. (2014). Redox-dependent lipoylation of mitochondrial proteins in *Plasmodium falciparum*. *Mol. Microbiol.* 94, 156–171. doi: 10.1111/mmi.12753
- Allary, M., Lu, J. Z., Zhu, L., and Prigge, S. T. (2007). Scavenging of the cofactor lipoate is essential for the survival of the malaria parasite *Plasmodium falciparum*. *Mol. Microbiol.* 63, 1331–1344. doi: 10.1111/j.1365-2958.2007.05592.x
- Berg, A., de Kok, A., and Vervoort, J. (1994). Sequential 1H and 15N nuclear magnetic resonance assignments and secondary structure of the N-terminal lipoyl domain of the dihydrolipoyl transacetylase component of the pyruvate dehydrogenase complex from *Azotobacter vinelandii*. *Eur. J. Biochem.* 221, 87–100. doi: 10.1111/j.1432-1033.1994.tb18717.x
- Brown, P. H., and Beckett, D. (2005). Use of binding enthalpy to drive an allosteric transition. *Biochemistry* 44, 3112–3121. doi: 10.1021/bi047792k
- Cao, X., and Cronan, J. E. (2015). The *Streptomyces coelicolor* lipoate-protein ligase is a circularly permuted version of the *Escherichia coli* enzyme composed of discrete interacting domains. *J. Biol. Chem.* 290, 7280–7290. doi: 10.1074/jbc.M114.626879
- Cao, X., Hong, Y., Zhu, L., Hu, Y., and Cronan, J. E. (2018a). Development and retention of a primordial moonlighting pathway of protein modification in the absence of selection presents a puzzle. *Proc. Natl. Acad. Sci. U.S.A.* 115, 647–655. doi: 10.1073/pnas.1718653115
- Cao, X., Zhu, L., Song, X., Hu, Z., and Cronan, J. E. (2018b). Protein moonlighting elucidates the essential human pathway catalyzing lipoic acid assembly on its cognate enzymes. *Proc. Natl. Acad. Sci. U.S.A.* 115, E7063–E7072. doi: 10.1073/pnas.1805862115
- Chen, Q., Qiu, S., Li, H., Lin, C., Luo, Y., Ren, W., et al. (2018). A novel approach for rapid high-throughput selection of recombinant functional rat monoclonal antibodies. *BMC Immunol.* 19:35. doi: 10.1186/s12865-018-0274-8

ETHICS STATEMENT

The animal experiment was approved by the Institutional Animal Care and Use Committee of Harbin Veterinary Research Institute.

AUTHOR CONTRIBUTIONS

KZ constructed all plasmids and analyzed the enzyme activities. HC solved the protein structure. JJ and NW produced the monoclonal antibodies. GM and JH expressed the Mhp-Lpl protein. YF wrote the manuscript JX provided *M. hyopneumoniae*. HZ collected and analyzed the structural data. HL designed the experiments and wrote the manuscript.

FUNDING

This work was supported by the Central Public-interest Scientific Institution Basal Research Fund (1610302017014), a Natural Science Foundation of China grant (31670753 to HZ), the Guangdong Science and Technology Program (2017B030301018 to HZ), and research grants from the Shenzhen Science and Technology Innovation Committee (JCYJ20160608140912962 and ZDSYS20140509142721429 to HZ).

ACKNOWLEDGMENTS

We would like to thank the technician Yuming Yan at Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences (CAAS), and staff from BL17U1 and BL19U1 beamlines at the SSRF for technical support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcimb.2020.00156/full#supplementary-material>

- Christensen, Q. H., Hagar, J. A., O'Riordan, M. X., and Cronan, J. E. (2011a). A complex lipote utilization pathway in *Listeria monocytogenes*. *J. Biol. Chem.* 286, 31447–31456. doi: 10.1074/jbc.M111.273607
- Christensen, Q. H., Martin, N., Mansilla, M. C., de Mendoza, D., and Cronan, J. E. (2011b). A novel amidotransferase required for lipote acid cofactor assembly in *Bacillus subtilis*. *Mol. Microbiol.* 80, 350–363. doi: 10.1111/j.1365-2958.2011.07598.x
- Collaborative Computational Project, N. (1994). The CCP4 suite: programs for protein crystallography. *Acta Crystallogr. D Biol. Crystallogr.* 50, 760–763. doi: 10.1107/S0907444994003112
- Cowtan, K. D., and Zhang, K. Y. (1999). Density modification for macromolecular phase improvement. *Prog. Biophys. Mol. Biol.* 72, 245–270. doi: 10.1016/s0079-6107(99)00008-5
- Cronan, J. E. (2014). Biotin and lipote acid: synthesis, attachment, and regulation. *EcoSal Plus* 6, 1–39. doi: 10.1128/ecosalplus.ESP-0001-2012
- Cronan, J. E., Zhao, X., and Jiang, Y. (2005). Function, attachment and synthesis of lipote acid in *Escherichia coli*. *Adv. Microbial Physiol.* 50, 103–146. doi: 10.1016/S0065-2911(05)50003-1
- Douglas, P., Kriek, M., Bryant, P., and Roach, P. L. (2006). Lipoyl synthase inserts sulfur atoms into an octanoyl substrate in a stepwise manner. *Angew. Chem. Int. Ed. Engl.* 45, 5197–5199. doi: 10.1002/anie.200601910
- Duckworth, B. P., Geders, T. W., Tiwari, D., Boshoff, H. I., Sibbald, P. A., Barry, C. E., et al. (2011). Bisubstrate adenylation inhibitors of biotin protein ligase from *Mycobacterium tuberculosis*. *Chem. Biol.* 18, 1432–1441. doi: 10.1016/j.chembiol.2011.08.013
- Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010). Features and development of coot. *Acta Crystallogr. D Biol. Crystallogr.* 66, 486–501. doi: 10.1107/S0907444910007493
- Ewald, R., Hoffmann, C., Florian, A., Neuhaus, E., Fernie, A. R., and Bauwe, H. (2014). Lipote-protein ligase and octanoyltransferase are essential for protein lipoylation in mitochondria of *Arabidopsis*. *Plant Physiol.* 165, 978–990. doi: 10.1104/pp.114.238311
- Feng, J., Paparella, A. S., Booker, G. W., Polyak, S. W., and Abell, A. D. (2016). Biotin protein ligase is a target for new antibacterials. *Antibiotics* 5:26. doi: 10.3390/antibiotics5030026
- Fujiwara, K., Hosaka, H., Matsuda, M., Okamura-Ikeda, K., Motokawa, Y., Suzuki, M., et al. (2007). Crystal structure of bovine lipoyltransferase in complex with lipoyl-AMP. *J. Mol. Biol.* 371, 222–234. doi: 10.1016/j.jmb.2007.05.059
- Fujiwara, K., Maita, N., Hosaka, H., Okamura-Ikeda, K., Nakagawa, A., and Taniguchi, H. (2010). Global conformational change associated with the two-step reaction catalyzed by *Escherichia coli* lipote-protein ligase A. *J. Biol. Chem.* 285, 9971–9980. doi: 10.1074/jbc.M109.078717
- Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1992). Expression of mature bovine H-protein of the glycine cleavage system in *Escherichia coli* and *in vitro* lipoylation of the apoforn. *J. Biol. Chem.* 267, 20011–20016.
- Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1997). Cloning and expression of a cDNA encoding bovine lipoyltransferase. *J. Biol. Chem.* 272, 31974–31978. doi: 10.1074/jbc.272.51.31974
- Fujiwara, K., Toma, S., Okamura-Ikeda, K., Motokawa, Y., Nakagawa, A., and Taniguchi, H. (2005). Crystal structure of lipote-protein ligase A from *Escherichia coli*. Determination of the lipote acid-binding site. *J. Biol. Chem.* 280, 33645–33651. doi: 10.1074/jbc.M505010200
- Gunther, S., Wallace, L., Patzewitz, E.-M., McMillan, P. J., Storm, J., Wrenger, C., et al. (2007). Apicoplast lipote acid protein ligase B is not essential for *Plasmodium falciparum*. *PLoS Pathog.* 3:e189. doi: 10.1371/journal.ppat.0030189
- Hao, Q. (2004). ABS: a program to determine absolute configuration and evaluate anomalous scatterer substructure. *J. Appl. Crystallogr.* 37, 498–499. doi: 10.1107/S0021889804008696
- Hermes, F. A., and Cronan, J. E. (2013). The role of the *Saccharomyces cerevisiae* lipote protein ligase homologue, Lip3, in lipote acid synthesis. *Yeast* 30, 415–427. doi: 10.1002/yea.2979
- Jordan, S. W., and Cronan, J. E. Jr. (2003). The *Escherichia coli* lipB gene encodes lipoyl (octanoyl)-acyl carrier protein:protein transferase. *J. Bacteriol.* 185, 1582–1589. doi: 10.1128/jb.185.5.1582-1589.2003
- Kim, D. J., Kim, K. H., Lee, H. H., Lee, S. J., Ha, J. Y., Yoon, H. J., et al. (2005). Crystal structure of lipote-protein ligase A bound with the activated intermediate: insights into interaction with lipoyl domains. *J. Biol. Chem.* 280, 38081–38089. doi: 10.1074/jbc.M507284200
- Ma, Q., Zhao, X., Eddine, A. N., Geerlof, A., Li, X., Cronan, J. E., et al. (2006). The *Mycobacterium tuberculosis* LipB enzyme functions as a cysteine/lysine dyad acyltransferase. *Proc. Natl. Acad. Sci. U.S.A.* 103, 8662–8667. doi: 10.1073/pnas.0510436103
- Maes, D., Segales, J., Meyns, T., Silbila, M., Pieters, M., and Haesebrouck, F. (2008). Control of *Mycoplasma hyopneumoniae* infections in pigs. *Vet. Microbiol.* 126, 297–309. doi: 10.1016/j.vetmic.2007.09.008
- Mare, C. J., and Switzer, W. P. (1965). New species: *Mycoplasma hyopneumoniae*; a causative agent of virus pig pneumonia. *Vet. Med. Small Ani. Clin.* 60, 841–846.
- Martin, N., Christensen, Q. H., Mansilla, M. C., Cronan, J. E., and de Mendoza, D. (2011). A novel two-gene requirement for the octanoyltransfer reaction of *Bacillus subtilis* lipote acid biosynthesis. *Mol. Microbiol.* 80, 335–349. doi: 10.1111/j.1365-2958.2011.07597.x
- McManus, E., Luisi, B. F., and Perham, R. N. (2006). Structure of a putative lipote protein ligase from *Thermoplasma acidophilum* and the mechanism of target selection for post-translational modification. *J. Mol. Biol.* 356, 625–637. doi: 10.1016/j.jmb.2005.11.057
- Miller, J. R., Busby, R. W., Jordan, S. W., Cheek, J., Henshaw, T. F., Ashley, G. W., et al. (2000). *Escherichia coli* LipA is a lipoyl synthase: *in vitro* biosynthesis of lipoylated pyruvate dehydrogenase complex from octanoyl-acyl carrier protein. *Biochemistry* 39, 15166–15178. doi: 10.1021/bi002060n
- Morris, R. J., Perrakis, A., and Lamzin, V. S. (2003). ARP/wARP and automatic interpretation of protein electron density maps. *Methods Enzymol.* 374, 229–244. doi: 10.1016/S0076-6879(03)74011-7
- Morris, T. W., Reed, K. E., and Cronan, J. E. Jr. (1994). Identification of the gene encoding lipote-protein ligase A of *Escherichia coli*. Molecular cloning and characterization of the lplA gene and gene product. *J. Biol. Chem.* 269, 16091–16100.
- Morris, T. W., Reed, K. E., and Cronan, J. E. Jr. (1995). Lipote acid metabolism in *Escherichia coli*: the lplA and lipB genes define redundant pathways for ligation of lipoyl groups to apoprotein. *J. Bacteriol.* 177, 1–10. doi: 10.1128/JB.177.1.1-10.1995
- Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., et al. (2011). REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr. D Biol. Crystallogr.* 67, 355–367. doi: 10.1107/S0907444911001314
- Panjikar, S., Parthasarathy, V., Lamzin, V. S., Weiss, M. S., and Tucker, P. A. (2005). Auto-rickshaw: an automated crystal structure determination platform as an efficient tool for the validation of an X-ray diffraction experiment. *Acta Crystallogr. D Biol. Crystallogr.* 61, 449–457. doi: 10.1107/S0907444905001307
- Perrakis, A., Harkiolaki, M., Wilson, K. S., and Lamzin, V. S. (2001). ARP/wARP and molecular replacement. *Acta Crystallogr. D Biol. Crystallogr.* 57, 1445–1450. doi: 10.1107/s0907444901014007
- Pompidor, G., Maury, O., Vicat, J., and Kahn, R. (2010). A dipicolinate lanthanide complex for solving protein structures using anomalous diffraction. *Acta Crystallogr. D Biol. Crystallogr.* 66, 762–769. doi: 10.1107/S0907444910010954
- Posner, M. G., Upadhyay, A., Bagby, S., Hough, D. W., and Danson, M. J. (2009). A unique lipoylation system in the Archaea. *Lipoylation in Thermoplasma acidophilum requires two proteins*. *FEBS J.* 276, 4012–4022. doi: 10.1111/j.1742-4658.2009.07110.x
- Posner, M. G., Upadhyay, A., Crennell, S. J., Watson, A. J. A., Dorus, S., Danson, M. J., et al. (2013). Post-translational modification in the archaea: structural characterization of multi-enzyme complex lipoylation. *Biochem. J.* 449, 415–425. doi: 10.1042/BJ20121150
- Ramaswamy, A. V., and Maurelli, A. T. (2010). *Chlamydia trachomatis* serovar L2 can utilize exogenous lipote acid through the action of the lipote acid ligase LplA1. *J. Bacteriol.* 192, 6172–6181. doi: 10.1128/JB.00717-10
- Reche, P., and Perham, R. N. (1999). Structure and selectivity in post-translational modification: attaching the biotinyl-lysine and lipoyl-lysine swinging arms in multifunctional enzymes. *EMBO J.* 18, 2673–2682. doi: 10.1093/emboj/18.10.2673
- Reed, L. J., and Hackert, M. L. (1990). Structure-function relationships in dihydrolipoamide acyltransferases. *J. Biol. Chem.* 265, 8971–8974.
- Reed, L. J., Koike, M., Levitch, M. E., and Leach, F. R. (1958). Studies on the nature and reactions of protein-bound lipote acid. *J. Biol. Chem.* 232, 143–158.

- Schneider, T. R., and Sheldrick, G. M. (2002). Substructure solution with SHELXD. *Acta Crystallogr. D Biol. Crystallogr.* 58, 1772–1779. doi: 10.1107/s0907444902011678
- Sheldrick, G. M. (2002). Macromolecular phasing with SHELXE. *Z Kristallogr.* 217, 644–650. doi: 10.1524/zkri.217.12.644.20662
- Sheldrick, G. M. (2010). Experimental phasing with SHELXC/D/E: combining chain tracing with density modification. *Acta Crystallogr. D Biol. Crystallogr.* 66, 479–485. doi: 10.1107/S0907444909038360
- Smith, A. R., Shenvi, S. V., Widlansky, M., Suh, J. H., and Hagen, T. M. (2004). Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. *Curr. Med. Chem.* 11, 1135–1146. doi: 10.2174/0929867043365387
- Terwilliger, T. C. (2003). SOLVE and RESOLVE: automated structure solution and density modification. *Methods Enzymol.* 374, 22–37. doi: 10.1016/S0076-6879(03)74002-6
- Wang, M., Wang, Q., Gao, X., and Su, Z. (2017). Conditional knock-out of lipoic acid protein ligase 1 reveals redundancy pathway for lipoic acid metabolism in *Plasmodium berghei* malaria parasite. *Parasites Vectors* 10:315. doi: 10.1186/s13071-017-2253-y
- Wang, Q.-S., Zhang, K. H., Cui, Y., Wang, Z.-J., Pan, Q.-Y., Liu, K., et al. (2018). Upgrade of macromolecular crystallography beamline BL17U1 at SSRF. *Nucl. Sci. Tech.* 29:68. doi: 10.1007/s41365-018-0398-9
- Zhao, X., Miller, J. R., and Cronan, J. E. (2005). The reaction of LipB, the octanoyl-[acyl carrier protein]:protein N-octanoyltransferase of lipoic acid synthesis, proceeds through an acyl-enzyme intermediate. *Biochemistry* 44, 16737–16746. doi: 10.1021/bi051865y

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhu, Chen, Jin, Wang, Ma, Huang, Feng, Xin, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.